Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis

Journal of Managed Care Pharmacy

Volumn 17, Issue 4, 2011, Pages 313-320

  Wong, Bruce J ^a   Cifaldi, Mary A ^a   Roy, Sanjoy ^a   Skonieczny, Dean C ^a   Stavrakas, Spyros ^a  

^a Bruce Wong and Associates Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; INFLIXIMAB; MEPREDNISONE; RITUXIMAB;

ADULT; AGED; ARTICLE; BILLING AND CLAIMS; DRUG COST; FINANCIAL MANAGEMENT; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; RHEUMATOID ARTHRITIS; UNITED STATES;

EID: 79960670101     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2011.17.4.313     Document Type: Article

References (22)

1. Birnbaum H, Pike C, Kaufman R, Maynchenko M, Kidolezi Y, Cifaldi M. Societal cost of rheumatoid arthritis patients in the U.S. Curr Med Res Opin. 2010;26(1):77-90.
2. Wiles NJ, Scott DG, Barrett EM, et al. Benchmarking: the five year outcome of rheumatoid arthritis assessed using a pain score, the Health Assessment Questionnaire, and the Short Form-36 (SF-36) in a community and a clinic based sample. Ann Rheum Dis. 2001;60(10):956-61.
3. Naz SM, Symmons DP. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21(5):871-83.
4. Helmick CG, Felson DT, Lawrence RC, et al. National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15-25. Available at: http://onlinelibrary.wiley.com/doi/10.1002/art.23177/pdf. Accessed April 23, 2011.
5. Wong M, Ziring D, Korin Y, et al. TNFα blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008;126(2):121-36. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291518/pdf/ nihms42588.pdf. Accessed April 23, 2011.
6. Feely MG, O'Dell JR. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis. Curr Opin Rheumatol. 2010;22(3):316-20.
7. Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. Am J Med. 2007;120(11):936-39.
8. Thompson A. Practical aspects of therapeutic intervention in rheumatoid arthritis. J Rheumatol Suppl. 2009;82:39-41.
9. Tyler LS, Cole SW, May JR, et al. ASHP Expert Panel on Formulary Management. ASHP guidelines on the pharmacy and therapeutics committee and the formulary system. Am J Health Syst Pharm. 2008;65(13):1272-83.
10. Davies A, Cifaldi MA, Segurado OG, Weisman MH. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J Rheumatol. 2009;36(1):16-26.
11. Ollendorf DA, Klingman D, Hazard E, Ray S. Differences in annual medication costs and rates of dosage increase between tumor necrosis factorantagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther. 2009;31(4):825-35.
12. Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F. Biologic drugs for rheumatoid arthritis in the Medicare program: a costeffectiveness analysis. Arthritis Rheum. 2008;58(4):939-46. Available at: http://onlinelibrary.wiley.com/doi/10.1002/art.23374/pdf. Accessed April 23, 2011.
13. Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin. 2008;24(8):2229-40.
14. Berger A, Edelsberg J, Li TT, Maclean JR, Oster G. Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother. 2005;39(12):2021-25.
15. Etemad L, Yu EB, Wanke LA. Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interface. 2005;18(4):21-27.
16. Remicade (infliximab). Centocor Ortho Biotech Inc. Revised February 2011. Available at: http://www.remicade.com/remicade/assets/HCP_PPI.pdf. Accessed April 23, 2011.
17. Orencia (abatacept). Bristol Myers Squibb Inc. Revised August 2009. Available at: http://packageinserts.bms.com/pi/pi_orencia.pdf. Accessed April 23, 2011.
18. Rituxan (Rituximab). Genentech, Inc. Revised April 2011. Available at: http://www.gene.com/gene/products/information/pdf/rituxan-prescribing. pdf. Accessed April 23, 2011.
19. Kruse GB, Amonkar MM, Smith G, Skonieczny DC, Stavrakas S. Analysis of costs associated with administration of intravenous singledrug therapies in metastatic breast cancer in a U.S. population. J Manag Care Pharm. 2008;14(9):844-57. Available at: http://www.amcp.org/data/ jmcp/844-857.pdf.
20. Kielhorn A, Porter D, Diamantopoulos A, Lewis G. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. Curr Med Res Opin. 2008;24(9):2639-50.
21. Vera-Llonch M, Massarotti E, Wolfe F, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Rheumatology (Oxford). 2008;47(4):535-41. Available at: http://rheumatology.oxfordjournals.org/content/ 47/4/535.full.pdf+html. Accessed April 23, 2011.
22. Yazici Y, McMorris BJ, Darkow T, Rosenblatt LC. Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009;27(6):907-13.